Pfizer Confident In Lipitor Backup Plan, But Wall Street Seems On The Fence
Executive Summary
Although Pfizer maintains it has a reasonably failsafe plan in place to weather the loss of exclusivity for its blockbuster cholesterol drug Lipitor and other products in coming, Wall Street appears less confident in the drug maker's ability to come out ahead
You may also be interested in...
Eager To Counter Patent Cliff, Falling Share Price, Pfizer Forges New Partnerships Around The World, Inside China
BEIJING - The New York-headquartered Pfizer Inc. entered into an agreement with the Osaka-based Takeda Pharmaceutical to co-promote Takeda's diabetes drug Actos (pioglitazone) inside China in part because the American outfit can rely on its vastly expanded sales network here following its merger with Wyeth
Pfizer Matches Lilly In Grant Spending For 1st Quarter; Fibromyalgia Is Focus
Pfizer and Lilly dispensed comparable amounts in grants during the first quarter of 2008, as revealed by Pfizer's inaugural online posting of gifts and charitable donations, unveiled May 15
Pfizer Matches Lilly In Grant Spending For 1st Quarter; Fibromyalgia Is Focus
Pfizer and Lilly dispensed comparable amounts in grants during the first quarter of 2008, as revealed by Pfizer's inaugural online posting of gifts and charitable donations, unveiled May 15